Tao Chen
Research Subjects
Tao Chen has a total of 55 co-authors. Here are the top co-authors by number of shared publications:
- Abiyasi Nanding
Department of Pathology, Harbin Medical University Cancer Hospital, Harbin, Heilongjiang, Harbin, Heilongjiang, China
19 shared publications - Chen Song
Huayi Regeneration Technology Co., Ltd., Chengdu, China
19 shared publications - Da Pang
Department of Breast Surgery, Harbin Medical University Cancer Hospital, Harbin, 150081, China
19 shared publications - Dalin Li
Department of Breast Surgery, Harbin Medical University Cancer Hospital, Harbin, China
19 shared publications - Fang Fang
Department of Breast Surgery, Harbin Medical University Cancer Hospital, Harbin, China
19 shared publications - Guoqiang Zhang
Department of Breast Surgery, Harbin Medical University Cancer Hospital, Harbin, China
19 shared publications
Latest Publications
- Open Access
- 2 January 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Table S2 from Integrating ctDNA Dynamics and Sequential Organoid Drug Screening Enhances Breast Cancer Treatment Efficacy
Breast Cancer 90-Gene Panel and Probe Sequences
- 2 January 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table S2 from Integrating ctDNA Dynamics and Sequential Organoid Drug Screening Enhances Breast Cancer Treatment Efficacy
Breast Cancer 90-Gene Panel and Probe Sequences
- Open Access
- 2 January 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Figure S4 from Integrating ctDNA Dynamics and Sequential Organoid Drug Screening Enhances Breast Cancer Treatment Efficacy
Clearance of cfDNA in the culture supernatant of organoids
- 2 January 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure S4 from Integrating ctDNA Dynamics and Sequential Organoid Drug Screening Enhances Breast Cancer Treatment Efficacy
Clearance of cfDNA in the culture supernatant of organoids
- Open Access
- 2 January 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Figure S5 from Integrating ctDNA Dynamics and Sequential Organoid Drug Screening Enhances Breast Cancer Treatment Efficacy
Monitoring ctDNA to assess alpelisib-mediated reversal of pyrotinib resistance in her2-positive breast cancer
- 2 January 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure S5 from Integrating ctDNA Dynamics and Sequential Organoid Drug Screening Enhances Breast Cancer Treatment Efficacy
Monitoring ctDNA to assess alpelisib-mediated reversal of pyrotinib resistance in her2-positive breast cancer
- Open Access
- 2 January 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Figure S6 from Integrating ctDNA Dynamics and Sequential Organoid Drug Screening Enhances Breast Cancer Treatment Efficacy
Growth curves of four breast cancer organoid lines
- 2 January 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure S6 from Integrating ctDNA Dynamics and Sequential Organoid Drug Screening Enhances Breast Cancer Treatment Efficacy
Growth curves of four breast cancer organoid lines
- Open Access
- 2 January 2026
- Published by American Association for Cancer Research (AACR)
Data from Integrating ctDNA Dynamics and Sequential Organoid Drug Screening Enhances Breast Cancer Treatment Efficacy
Dynamic changes in ctDNA variant allele frequency reflect real-time therapeutic efficacy. Timely treatment modification guided by ctDNA variant allele frequency may enable precision selection of optimized regimens to counteract evolving resistance in breast cancer. In this study, we developed a therapeutic approach integrating ctDNA dynamics with sequential organoid drug screening to optimize breast cancer treatment. Targeted deep sequencing on plasma samples from 71 patients with breast cancer revealed that ctDNA clearance correlates with improved disease-free survival. Additionally, analysis of 40 breast cancer organoid models demonstrated the potential of organoid culture supernatants for comprehensive mutation profiling and drug sensitivity testing. Together, these findings suggest that combining ctDNA monitoring with organoid-based drug screening can guide adjustments to treatment strategies, offering a promising solution to optimize patient outcomes.Significance:Monitoring circulating tumor DNA in combination with drug screening of organoids enables dynamic, personalized breast cancer therapy adjustments to overcome resistance and improve treatment efficacy.
- 2 January 2026
- Published by American Association for Cancer Research (AACR)
Open AccessData from Integrating ctDNA Dynamics and Sequential Organoid Drug Screening Enhances Breast Cancer Treatment Efficacy
Dynamic changes in ctDNA variant allele frequency reflect real-time therapeutic efficacy. Timely treatment modification guided by ctDNA variant allele frequency may enable precision selection of optimized regimens to counteract evolving resistance in breast cancer. In this study, we developed a therapeutic approach integrating ctDNA dynamics with sequential organoid drug screening to optimize breast cancer treatment. Targeted deep sequencing on plasma samples from 71 patients with breast cancer revealed that ctDNA clearance correlates with improved disease-free survival. Additionally, analysis of 40 breast cancer organoid models demonstrated the potential of organoid culture supernatants for comprehensive mutation profiling and drug sensitivity testing. Together, these findings suggest that combining ctDNA monitoring with organoid-based drug screening can guide adjustments to treatment strategies, offering a promising solution to optimize patient outcomes.Significance:Monitoring circulating tumor DNA in combination with drug screening of organoids enables dynamic, personalized breast cancer therapy adjustments to overcome resistance and improve treatment efficacy.
- Open Access
- 2 January 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Table S3 from Integrating ctDNA Dynamics and Sequential Organoid Drug Screening Enhances Breast Cancer Treatment Efficacy
Sequences of primers and MGB probes for detecting mutations using digital PCR
- 2 January 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table S3 from Integrating ctDNA Dynamics and Sequential Organoid Drug Screening Enhances Breast Cancer Treatment Efficacy
Sequences of primers and MGB probes for detecting mutations using digital PCR
- Open Access
- 2 January 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Figure S8 from Integrating ctDNA Dynamics and Sequential Organoid Drug Screening Enhances Breast Cancer Treatment Efficacy
Normalized AUC values from the second round of drug screening for organoids with an increased ctDNA VAF after treatment with the initial sensitive drugs
- 2 January 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure S8 from Integrating ctDNA Dynamics and Sequential Organoid Drug Screening Enhances Breast Cancer Treatment Efficacy
Normalized AUC values from the second round of drug screening for organoids with an increased ctDNA VAF after treatment with the initial sensitive drugs
- Open Access
- 2 January 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Table S7 from Integrating ctDNA Dynamics and Sequential Organoid Drug Screening Enhances Breast Cancer Treatment Efficacy
Clinical and Sequencing Information of 40 Patients with Breast Cancer Organoids
- 2 January 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table S7 from Integrating ctDNA Dynamics and Sequential Organoid Drug Screening Enhances Breast Cancer Treatment Efficacy
Clinical and Sequencing Information of 40 Patients with Breast Cancer Organoids
- Open Access
- 2 January 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Figure S1 from Integrating ctDNA Dynamics and Sequential Organoid Drug Screening Enhances Breast Cancer Treatment Efficacy
Kaplan-Meier survival curves for disease-free survival (DFS) based on ctDNA clearance at T2, T3, and T4 time points
- 2 January 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure S1 from Integrating ctDNA Dynamics and Sequential Organoid Drug Screening Enhances Breast Cancer Treatment Efficacy
Kaplan-Meier survival curves for disease-free survival (DFS) based on ctDNA clearance at T2, T3, and T4 time points
- Open Access
- 2 January 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Table S4 from Integrating ctDNA Dynamics and Sequential Organoid Drug Screening Enhances Breast Cancer Treatment Efficacy
Clinical characteristics of 71 patients receiving neoadjuvant therapy
- 2 January 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table S4 from Integrating ctDNA Dynamics and Sequential Organoid Drug Screening Enhances Breast Cancer Treatment Efficacy
Clinical characteristics of 71 patients receiving neoadjuvant therapy